Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World study reveals gaps in lung cancer testing

NCT ID NCT05644808

Knowledge-focused Sponsor: US Oncology Research Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows over 1,000 people with newly diagnosed non-small cell lung cancer in community cancer clinics. Researchers want to see how many patients receive key biomarker test results before starting treatment, and what barriers (like tissue issues or insurance problems) cause delays. The goal is to understand real-world testing practices and improve access to personalized therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,002 people

The number who actually took part.

Started

Dec 2020

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This pragmatic study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced stage, treatment naive non-small cell lung cancer.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult subjects (18 years and older) with newly diagnosed early stage, locally advanced or metastatic non-small cell lung cancer * Eligible for systemic therapy based on the treating provider's assessment * Subjects who developed locally advanced or metastatic disease after receiving adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the development of locally advanced or metastatic disease * Subjects may be enrolled within 30 days of initiation of systemic therapy * Signed informed consent Exclusion Criteria: * Stage IA at the time of enrollment * Subjects with small cell lung cancer * Subjects with Unknown primary tumor origin

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carcinoma, non-small-cell lung are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carcinoma, non-small-cell lung

Contacts and locations

Locations

  • Illinois Cancer Specialists

    Niles, Illinois, 60714, United States

  • Maryland Oncology Hematology, P.A.

    Silver Spring, Maryland, 20904, United States

  • Minnesota Oncology Hematology, P.A.

    Minneapolis, Minnesota, 55404, United States

  • New York Oncology Hematology, P.C.

    Albany, New York, 12208, United States

  • Oncology Hematology Care Clinical Trials, LLC

    Cincinnati, Ohio, 45242, United States

  • Rocky Mountain Cancer Center

    Denver, Colorado, 80218, United States

  • Southern Cancer Center, PC

    Daphne, Alabama, 36526, United States

  • Texas Oncology - Fort Worth Cancer Center

    Fort Worth, Texas, 76104, United States

  • Texas Oncology - West Texas

    Abilene, Texas, 79606, United States

  • Texas Oncology- DFWW

    Arlington, Texas, 76012, United States

  • Texas Oncology- Northeast Texas

    Tyler, Texas, 75702, United States

  • Texas Oncology-Baylor Charles A. Sammons Cancer Center

    Dallas, Texas, 75246, United States

  • Texas Oncology-Dallas Presbyterian Hospital

    Dallas, Texas, 75231, United States

  • Texas Oncology-McAllen

    McAllen, Texas, 78503, United States

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia, 22031, United States

  • Virginia Oncology Associates

    Newport News, Virginia, 23606, United States

  • Willamette Valley Cancer Institute and Research Center

    Eugene, Oregon, 97401, United States

  • Woodlands Medical Specialists, PA

    Pensacola, Florida, 32503, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.